0 Items
Select Page

Chlamydia

Chlamydia infection is one of the most common sexually transmitted infections, caused by the bacterium Chlamydia trachomatis. Most people who are infected show no symptoms and when symptoms do develop, they can take a few weeks to show following infection.

The Native Antigen Company prepares antigenic preparations of Chlamydia trachomatis in cell culture for use in immunoassay development.

Chlamydia Background

Chlamydia trachomatis is a gram-negative obligate intracellular pathogen that belongs to the Chlamydiaceae family. Chlamydia trachomatis strains are divided into three biovars, which are further divided into fifteen serovars A, B, Ba, serovars C-K and serovars L1-L3. Chlamydia trachomatis serovars A-C cause eye infections known as trachoma. Serovars D-K are responsible for sexually transmitted genito-urinary tract infections in women and men. Chlamydia trachomatis serovars L1, L2 and L3 are responsible for a condition known as lymphogranuloma venereum (LGV) (Elwell, C).

Infection of the genito-urinary tract by C. trachomatis occurs in both men and women, and is the most common cause of bacterial sexually transmitted disease in the United States (CDC). The bacterium infects mucosal cells of the penis, vagina, mouth or anus during unprotected sexual intercourse with an individual infected with C. trachomatis. During its life cycle, the bacterium alternates between two forms, the infectious elementary body and the reticulate body – a non-infectious replicating form. The reticulate body replicates within a membrane-bound compartment within the cell and after several rounds of replication, develops into the infectious elementary body, which can then infect neighbouring cells (Elwell, C).

In women, C. trachomatis infects the cervix which may lead to cervicitis. However, 70-80% of women with C. trachomatis genital tract infection remain asymptomatic. In 10% of cases, the bacterium can infect the upper genital tract leading to pelvic inflammatory disease, scarring of the Fallopian tubes, ectopic pregnancies and infertility. C. trachomatis can also be transmitted to babies born to infected untreated mothers during childbirth, causing conjunctivitis or pneumonia.

Lymphogranuloma venereum (LGV) is a condition that affects the lymphatic system, causing a range of clinical symptoms including proctitis, lymphadenitis, arthritis and genital lymphedema. LGV is endemic in tropical and sub-tropical regions and primarily affects sexually active heterosexual individuals. However, reports suggest that cases of LGV are increasing in the developed world, particularly in homosexual populations. Both women and men can develop LGV, but men often develop and present with proctitis early after infection whereas women remain asymptomatic until later stages of the disease (Ceovic, R).

References

  1. Elwell C, Mirrashidi K, Engel J. 2016. Chlamydia cell biology and pathogenesis. Nat Rev Microbiol. Jun;14(6):385-400.

 

  1. Centers for Disease protection and Control; Chlamydia – CDC factsheet

 

  1. Ceovic R, Gulin SJ.2015. Lymphogranuloma venereum: diagnostic and treatment challenges. Infect Drug Resist. 2015 Mar 27;8:39-47.

Chlamydia Antigens

Our Chlamydia trachomatis antigen is prepared from infected cells, which are washed, disrupted and centrifuged to remove cellular debris. Chlamydia antigen production is scalable from 10ml to several litres.

Chlamydia Antibodies

The Native Antigen Company is pleased to offer a full panel of antibodies to Chlamydia proteins, including those specific for the MOMP of C. Trachomatis, and high affinity antibodies specific for Chlamydia LPS, binding to C. Trachomatis, C. pneumoniae and C. psittaci

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

We recently teamed-up with Virology Research Services (VRS) who tested a large panel of our viral antibodies in immunofluorescence applications. This work was funded by the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) through the...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

What should you call your favourite virus?

The International Committee on Taxonomy of Viruses (ICTV) meet regularly to ensure the taxonomy of viruses is kept logical and up-to-date in the face of an ever-increasing number of new viruses and genome sequences; discussed in here in Nature. This sometimes results...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

15 + 2 =

Live Customer Feedback

Dengue Antibodies

The Native Antigen Company is pleased to offer a full panel of serotype-specific antibodies to Dengue NS1, which are suitable for the development of serotype-specific immunoassays. These antibodies have been raised against our renowned mammalian-expressed, recombinant NS1 proteins. They show no cross-reactivity with other serotypes of Dengue, or other flaviviruses including Zika, Yellow Fever and West Nile.

In addition to NS1-specific antibodies, we offer a number of additional antibodies specific for envelope and membrane proteins.